Cubist Pharmaceuticals announced a voluntary recall of one lot of Cubicin (daptomycin for injection) 500mg in 10mL vials, following a consumer complaint of particulate matter.
Nature's Universe announced a voluntary recall of all lots of old Thinogenics product due to the presence of an undisclosed ingredient, to the user level.
The FDA announced a nationwide recall of seven lots of Propofol Injectable Emulsion 1% (Hospira), due to visible metal particles embedded in the glass to the user level.
The FDA announced the approval of Ragwitek (Ambrosia artemisiifolia; Merck), the first sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis.
The FDA has approved a new indication for Arzerra (ofatumumab; GlaxoSmithKline) to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.